United Kingdom: GSK v Wyeth, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2015-000002, 12 May 2016

Kluwer Patent Blog
March 9, 2017


Please refer to this post as: , 'United Kingdom: GSK v Wyeth, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2015-000002, 12 May 2016', Kluwer Patent Blog, March 9 2017, http://kluwerpatentblog.com/2017/03/09/united-kingdom-gsk-v-wyeth-high-court-of-justice-of-england-and-wales-chancery-division-patents-court-hp-2015-000002-12-may-2016/


The UK Patents Court upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK’s allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called “AgrEvo” obviousness), insufficiency and added matter.  The court also held that a number of the claims were infringed by GSK’s meningitis B vaccine, Bexsero.

A full summary of this case has been published on Kluwer IP Law.